11,677 Abbott Laboratories $ABT Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC grew its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 0.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,597,358 shares of the healthcare product maker’s stock after acquiring an additional 11,677 shares during the quarter. HighTower Advisors LLC owned 0.09% of Abbott Laboratories worth $157,867,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Farther Finance Advisors LLC lifted its position in Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock worth $8,339,000 after acquiring an additional 10,431 shares during the period. Juncture Wealth Strategies LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $658,000. Aureus Asset Management LLC increased its holdings in shares of Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the period. Thompson Investment Management Inc. increased its holdings in shares of Abbott Laboratories by 786.0% in the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after purchasing an additional 12,474 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth about $4,889,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $104.64 on Wednesday. The firm’s fifty day moving average is $103.89 and its two-hundred day moving average is $101.74. The firm has a market cap of $181.23 billion, a price-to-earnings ratio of 39.04, a PEG ratio of 1.88 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company’s revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $1.30 EPS. Research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s payout ratio is presently 94.03%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the sale, the executive vice president owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Wells Fargo & Company upped their target price on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. JPMorgan Chase & Co. cut their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, October 22nd. Barclays started coverage on shares of Abbott Laboratories in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target for the company. Finally, UBS Group decreased their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

View Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.